The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
DNA methylation profiling reveals a predominant immune component in breast cancers
Open accessAbstract
Breast cancer is a molecularly, biologically and clinically heterogeneous group of disorders. Understanding this diversity is essential to improving diagnosis and optimizing treatment. Both genetic and acquired epigenetic abnormalities participate in cancer, but the involvement of the epigenome in breast cancer and its contribution to the complexity of the disease are still poorly understood. By means of DNA methylation profiling of 248 breast tissues, we have highlighted the existence of previously unrecognized breast cancer groups that go beyond the currently known ‘expression subtypes’. Interestingly, we showed that DNA methylation profiling can reflect the cell type composition of the tumour microenvironment, and in particular a T lymphocyte infiltration of the tumours. Further, we highlighted a set of immune genes having high prognostic value in specific tumour categories. The immune component uncovered here by DNA methylation profiles provides a new perspective for the importance of the microenvironment in breast cancer, holding implications for better management of breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Phenotypic plasticity and the epigenetics of human disease
Feinberg, A. P. (2007) · Nature · doi:10.1038/nature05919 · Cited by 1,613
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492 · cited 3×
“Indeed, the heterogeneous nature of breast cancers as well as the presence of distinct molecular entities suggests the existence of multiple ‘cells of origin’ (Lim et al, 2009).”
Cited by
DNA methylation age of human tissues and cell types
Horvath, S. (2013) · Genome Biology · doi:10.1186/gb-2013-14-10-r115 · Cited by 7,075
DNA methylation profiling in the clinic: applications and challenges
Heyn, H., & Esteller, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3270 · Cited by 746
Evaluation of the Infinium Methylation 450K technology
Dedeurwaerder, S., Defrance, M., Calonne, E., Denis, H., Sotiriou, C., & Fuks, F. (2011) · Epigenomics · doi:10.2217/epi.11.105 · Cited by 569
Self-citationMolecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis
Terunuma, A., Putluri, N., Mishra, P., Mathé, E. A., Dorsey, T. H., Yi, M., Wallace, T. A., Issaq, H. J., Zhou, M., Killian, J. K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71180 · Cited by 428
“Others have described molecular subgroups in breast cancer based solely on global DNA methylation pattern (22, 30).”
Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M. F., Verfaillie, C., Grünewald, T. G. P., & Fendt, S.-M. (2017) · Nature Communications · doi:10.1038/ncomms15267 · Cited by 424
Mehner, C., Hockla, A., Miller, E., Ran, S., Radisky, D. C., & Radisky, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.1932 · Cited by 368
Demerath, E. W., Guan, W., Grove, M. L., Aslibekyan, S., Mendelson, M., Zhou, Y.-H., Hedman, Å. K., Sandling, J. K., Li, L.-A., Irvin, M. R., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv161 · Cited by 355
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
Haibe-Kains, B., Desmedt, C., Loi, S., Culhane, A. C., Bontempi, G., Quackenbush, J., & Sotiriou, C. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr545 · Cited by 313
Self-citationEpigenetics as a Therapeutic Target in Breast Cancer
Connolly, R., & Stearns, V. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9263-3 · Cited by 117
Nestor, C. E., Barrenäs, F., Wang, H., Lentini, A., Zhang, H., Bruhn, S., Jörnsten, R., Langston, M. A., Rogers, G., Gustafsson, M., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004059 · Cited by 92
“Indeed, a recent study reported that a significant proportion of the DNA methylation differences observed between breast tumours (N = 248) reflected the number of infiltrating Tcells, and was significantly associated with prognosis [17].”
BackgroundFine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation
Quarto, G., Li Greci, A., Bizet, M., Penning, A., Primac, I., Murisier, F., Garcia-Martinez, L., Borges, R. L., Gao, Q., Cingaram, P. K. R., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.009 · Cited by 50
Self-citationZhu, X., Fang, H., Gladysz, K., Barbour, J. A., & Wong, J. W. H. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.003 · Cited by 35
Metadata
- Authors
- Dedeurwaerder, S., Desmedt, C., Calonne, E., Singhal, S. K., Haibe‐Kains, B., Defrance, M., Michiels, S., Volkmar, M., Deplus, R., Luciani, J., Lallemand, F., Larsimont, D., Toussaint, J., Haussy, S., Rothé, F., Rouas, G., Metzger, O., Majjaj, S., Saini, K., Putmans, P., Hames, G., van Baren, N., Coulie, P. G., Piccart, M., Sotiriou, C., & Fuks, F.
- Venue
- EMBO Molecular Medicine
- Published
- 2011-11-16
- Volume
- 3
- Issue
- 12
- Pages
- 726-741
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2134345937
- Cited by
- 225
- References
- 4
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.